ESCAPE: an open-label trial of personalized immunotherapy in critically lll COVID-19 patients
Background: Macrophage activation-like syndrome (MALS) and complex immune
dysregulation (CID) often underlie acute respiratory distress (ARDS) in COVID-19. We …
dysregulation (CID) often underlie acute respiratory distress (ARDS) in COVID-19. We …
[HTML][HTML] Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial
J Sundén-Cullberg, P Chen, H Häbel, P Skorup… - PloS one, 2023 - journals.plos.org
Background Anakinra and tocilizumab are used for severe Covid-19, but only one previous
randomized controlled trial (RCT) has studied both. We performed a multi-center RCT …
randomized controlled trial (RCT) has studied both. We performed a multi-center RCT …
Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 the REMAP-CAP COVID-19 immune modulation therapy domain …
BACKGROUND The interleukin-6 receptor antagonist tocilizumab improves outcomes in
critically ill patients with coronavirus disease 2019 (COVID-19). However, the effectiveness …
critically ill patients with coronavirus disease 2019 (COVID-19). However, the effectiveness …
Interleukin-6 receptor antagonists in critically ill patients with Covid-19
Remap-Cap Investigators - New England Journal of Medicine, 2021 - Mass Medical Soc
Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
[HTML][HTML] Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab
A Langer-Gould, JB Smith, EG Gonzales… - International Journal of …, 2020 - Elsevier
Objective To examine outcomes among patients who were treated with the targeted anti-
cytokine agents, anakinra or tocilizumab, for COVID-19-related cytokine storm (COVID19 …
cytokine agents, anakinra or tocilizumab, for COVID-19-related cytokine storm (COVID19 …
Anakinra and intravenous IgG versus tocilizumab in the treatment of COVID-19 pneumonia
M Zantah, ED Castillo, AJ Gangemi, M Patel… - MedRxiv, 2020 - medrxiv.org
Background COVID-19 can lead to acute respiratory failure and an exaggerated
inflammatory response. Studies have suggested promising outcomes using monoclonal …
inflammatory response. Studies have suggested promising outcomes using monoclonal …
Interleukin-6 receptor antagonists in critically ill patients with Covid-19–preliminary report
Remap-Cap Investigators, AC Gordon, PR Mouncey… - MedRxiv, 2021 - medrxiv.org
Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
[HTML][HTML] Tocilizumab versus anakinra in COVID-19: results from propensity score matching
R Arcani, F Correard, P Suchon, G Kaplanski… - Frontiers in …, 2023 - frontiersin.org
Background Tocilizumab and anakinra are anti-interleukin drugs to treat severe coronavirus
disease 2019 (COVID-19) refractory to corticosteroids. However, no studies compared the …
disease 2019 (COVID-19) refractory to corticosteroids. However, no studies compared the …
Efficacy and safety of sarilumab in hospitalized patients with coronavirus disease 2019: a randomized clinical trial
S Sivapalasingam, DJ Lederer, R Bhore… - Clinical Infectious …, 2022 - academic.oup.com
Background Open-label platform trials and a prospective meta-analysis suggest efficacy of
anti–interleukin (IL)-6R therapies in hospitalized patients with coronavirus disease 2019 …
anti–interleukin (IL)-6R therapies in hospitalized patients with coronavirus disease 2019 …
[HTML][HTML] Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 …
O Hermine, X Mariette, R Porcher… - European …, 2022 - Eur Respiratory Soc
Background Our objective was to determine whether anti-interleukin (IL)-6 receptors
improve outcomes of critically ill patients with coronavirus disease 2019 (COVID-19) …
improve outcomes of critically ill patients with coronavirus disease 2019 (COVID-19) …